EGLN3: Prolyl hydroxylase EGLN3
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as PKM, TELO2, ATF4, GPX4 and HIF1A.
- Drugs that act on it: 2
- With a US drug page: 1
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Vadadustat | Approved | Egl nine homolog 3 inhibitor | Inhibitor | Boxed warning |
| Molidustat | — | Egl nine homolog 3 inhibitor | Inhibitor | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Anemia
- 0.60
- Chronic renal failure syndrome
- 0.37
- Placenta praevia
- 0.36
- Stage 5 chronic kidney disease
- 0.33
- Abnormality of the skeletal system
- 0.32
- Refractive error
- 0.30
- Liver disorder
- 0.30
- Placental abruption
- 0.29
- Facial pain
- 0.28
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- EGLN3
Drugs and mechanisms are from ChEMBL CHEMBL5705 (CC BY-SA 3.0). Gene name, function (UniProt Q9H6Z9, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets